<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01516151</url>
  </required_header>
  <id_info>
    <org_study_id>PRT-API-NKPL66-CT-PIIB</org_study_id>
    <nct_id>NCT01516151</nct_id>
  </id_info>
  <brief_title>Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia</brief_title>
  <official_title>A Randomized Open-label Dose-ranging, Multi-center Trial to Assess the Safety and Efficacy of NKPL66(CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acasti Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JSS Medical Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Acasti Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of 0.5, 1.0, 2.0 and 4.0 g/ day of CaPre™ in reducing fasting plasma&#xD;
      serum triglycerides over a four week period in patients with mild-to-high&#xD;
      hypertriglyceridemia as compared to the standard of care alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The data generated from preclinical studies, as well as data accumulated from preclinical and&#xD;
      clinical studies conducted with the precursor of CaPre™, NKO® , a natural health product&#xD;
      (NPN: 80006416), have shown that CaPre™ is a safe product and well tolerated. In addition,&#xD;
      there are preclinical data demonstrating that CaPre™ is effective in reducing circulating&#xD;
      plasma concentrations of triglycerides. This effect is also accompanied by the regulation of&#xD;
      other blood lipids, glucose tolerance and inflammatory biomarkers. These studies have been&#xD;
      conducted in several preclinical adult phenotypes: (1) Healthy Sprague-Dawley (SD) rats, (2)&#xD;
      obese and dyslipidemic Zucker Diabetic Fatty (ZDF) rats and(3-5) in three distinct murine&#xD;
      phenotypes (normal wild-type C57BL/6, human ApoA-I transgenic mice and homozygous&#xD;
      LDL-receptor knockout).&#xD;
&#xD;
      As the prevalence of cardiometabolic disorders progressively increase over the years, it is&#xD;
      expected that there will be an augmentation in the necessity for new anti-dyslipidemic&#xD;
      medications that can most importantly be added in combination to other treatments. Current&#xD;
      treatment methods address a specific target indication, but do not offer complete management&#xD;
      of dyslipidemia.&#xD;
&#xD;
      We are now left with the option to either inadequately treat patients suffering from&#xD;
      cardiovascular and metabolic disorders or, to prescribe combination treatments hoping to&#xD;
      address the risk factors while mitigating their known side effects. A treatment gap exists&#xD;
      since there is no medication that increases HDL-cholesterol and reduces triglycerides while&#xD;
      reducing LDL-cholesterol without side effects.&#xD;
&#xD;
      At present there is a need to assess the effectiveness of CaPre™ in reducing triglycerides in&#xD;
      patients with high hypertriglyceridemia. The current study will address these issues and will&#xD;
      generate the evidence that will be required to determine whether this product could be&#xD;
      effectively used in the clinical management of this patient population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in fasting blood circulating serum TGs</measure>
    <time_frame>Between baseline and 4 weeks of treatment.</time_frame>
    <description>The percent change in fasting blood circulating serum TGs between baseline and 4 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in fasting plasma TGs</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
    <description>Absolute change in fasting plasma TGs;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients achieving target TG fasting plasma levels</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage (%) of patients achieving target TG fasting plasma levels (TG&lt;1.7 mmol/L);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma LDL-C, VLDL-C, HDL-C, total cholesterol, hs-CRP and non-HDL</measure>
    <time_frame>Between baseline and 4 and 8 weeks of treatment</time_frame>
    <description>Absolute change in fasting plasma LDL-C, VLDL-C, HDL-C, total cholesterol, hs-CRP and non-HDL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma concentrations of LDL-C, VLDL-C, HDL-C, total cholesterol, hs-CRP and non-HDL</measure>
    <time_frame>Between baseline and 4 and 8 weeks of treatment</time_frame>
    <description>Percentage (%) change in fasting plasma concentrations of LDL-C, VLDL-C, HDL-C, total cholesterol, hs-CRP and non-HDL;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculated ratios</measure>
    <time_frame>The percent change in fasting blood circulating serum TGs Between baseline and 4 and 8 weeks of treatment.</time_frame>
    <description>Calculated Ratios:&#xD;
Total cholesterol : HDL-C&#xD;
LDL-C : HDL-C&#xD;
TGs : HDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma concentrations of biomarkers</measure>
    <time_frame>Between baseline and 4 and 8 weeks of treatment</time_frame>
    <description>Absolute and percent (%) change in fasting plasma concentrations of biomarkers;&#xD;
Glycated Hemoglobin (HbA1c)&#xD;
Glucose&#xD;
Creatinine phosphokinase (CPK)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">289</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5g total CaPre™ from baseline to week 4 and 1.0g total CaPre™ from week 4 to week 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.0g total CaPre™ from baseline to week 4 and 2.0g total CaPre™ from week 4 to week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.0g total CaPre™ from baseline to week 4 and 4.0g total CaPre™ from week 4 to week 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4.0g total CaPre™ from baseline to week 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CaPre™</intervention_name>
    <description>1 capsule of 0.5g total CaPre™ for 4 weeks followed by one 1.0g capsule per day for an additional 4 weeks</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CaPre™</intervention_name>
    <description>1 capsule of 1.0g total CaPre™ for 4 weeks followed by two 1.0g capsules per day for an additional 4 weeks</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CaPre™</intervention_name>
    <description>2 capsules of 1.0g total CaPre™ for 4 weeks followed by 4 capsules of 1.0g total per day for an additional 4 weeks.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipid Lowering Medication</intervention_name>
    <description>Patient will be treated as per the Standard of care.</description>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CaPre™</intervention_name>
    <description>4 capsules of 1 g total per day for 8 weeks.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female adults aged 18 to 75 years;&#xD;
&#xD;
          -  Fasting plasma levels of TG &gt; 2.28 and &lt; 10 mmol/L (200 and 877 mg/dL) on two&#xD;
             occasions within 2 weeks (screening and baseline/part 1 visits).&#xD;
&#xD;
          -  Patients who are currently not on pharmacotherapy for hyperlipidemia and according to&#xD;
             the judgement of the physician and Canadian Guidelines for the Diagnosis and Treatment&#xD;
             of Dyslipidemia initiation of drug therapy is not indicated for the duration of the&#xD;
             study.&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  Patients currently treated with statins and according to the judgement of the&#xD;
             physician and the Canadian Guidelines for the Diagnosis and Treatment of Dyslipidemia&#xD;
             a change in their current drug regimen is not indicated for the duration of the study.&#xD;
&#xD;
          -  Patients treated with statin must be on stable dose for at least 6 weeks prior to&#xD;
             screening;&#xD;
&#xD;
          -  Patients are willing to follow the NCEP Step 1 Diet (see Appendix 4) for the duration&#xD;
             of the study;&#xD;
&#xD;
          -  Female participants of childbearing potential (i.e. not surgically sterilized or&#xD;
             post-menopausal greater than one year) must have negative serum pregnancy test and&#xD;
             must be using an effective birth control method, defined as:&#xD;
&#xD;
               -  continuous use of oral or long acting injected contraceptive for at least 2&#xD;
                  months prior to study entry, or;&#xD;
&#xD;
               -  use of an intra-uterine device or implantable contraceptive, or;&#xD;
&#xD;
               -  use of double barrier methods of birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any concomitant medication which in the opinion of the investigator would preclude the&#xD;
             patient from successfully participating in the study;&#xD;
&#xD;
          -  Women who are pregnant or that are breast feeding;&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days from initiation of the study;&#xD;
&#xD;
          -  Participants with a high risk for cardiovascular disease; (The definition of high-risk&#xD;
             individuals will follow that of the 2009 Canadian Guidelines and include a) FRS &gt;= 20%&#xD;
             10-year risk; b) All patients with uncontrolled diabetes (DCA guidelines) and c)&#xD;
             Evidence of atherosclerosis -when this evidence was ascertained when clinically&#xD;
             indicated);&#xD;
&#xD;
          -  Systolic blood pressure &gt; 140 mmHg and/or diastolic blood pressure &gt; 90 mmHg. In&#xD;
             diabetic patients, systolic blood pressure &gt; 130 mmHg and/or diastolic blood pressure&#xD;
             &gt; 90 mmHg.&#xD;
&#xD;
          -  History of stroke, intermittent claudication or transient ischemic attack;&#xD;
&#xD;
          -  Known unstable (uncontrolled) cardiac disease, within the last 6 months:&#xD;
&#xD;
          -  Patient with a clinically significant abnormal ECG at screening.&#xD;
&#xD;
          -  Patients with uncontrolled diabetes mellitus, with HbA1c &gt; 7.0%;&#xD;
&#xD;
          -  Known diagnosis of hypoglycemia&#xD;
&#xD;
          -  Evidence of active renal disease indicated by a fasting estimated glomerular&#xD;
             filtration rate (eGFR) of &lt; 60 ml/min per 1.73 m2;&#xD;
&#xD;
          -  Increased plasma levels (&gt;ULN) of amylase (as per respective lab upper limits) and /&#xD;
             or lipase (&gt;160 IU/L) or any indication of pancreatitis (increased alcohol&#xD;
             consumption, gallstones);&#xD;
&#xD;
          -  History of pancreatitis;&#xD;
&#xD;
          -  Use of any lipid lowering medication other than statins (e.g niacin, fibrates or&#xD;
             ezetimibe) and/or lipid lowering NHP within 6 weeks prior to the screening visit;&#xD;
&#xD;
          -  Intake of &gt; 2 servings per week of fish or regimented use of fish oil/omega-3&#xD;
             supplements within 6 weeks prior to the screening visit;&#xD;
&#xD;
          -  Intake of fortified foods containing plant sterols within 6 weeks prior to the&#xD;
             screening visit;&#xD;
&#xD;
          -  Known HIV or Hepatitis B or C positive;&#xD;
&#xD;
          -  Patients with osteoporosis and hormone sensitive conditions;&#xD;
&#xD;
          -  Patients with uncontrolled asthma as defined by the 2010 Consensus Summary of the&#xD;
             Canadian Thoracic Society;&#xD;
&#xD;
          -  Known seafood allergy or allergy to any of the medicinal or non-medicinal ingredients&#xD;
             of the study medication, including:&#xD;
&#xD;
               -  Omega-3 fatty acids (including EPA and DHA)&#xD;
&#xD;
               -  Phospholipids (mainly phosphatidylcholine)&#xD;
&#xD;
               -  Astaxanthin&#xD;
&#xD;
               -  Bovine gelatin&#xD;
&#xD;
          -  Coagulopathy or on anticoagulants. Platelet aggregation inhibitors (such as aspirin or&#xD;
             clopidogrel but not heparin) are permitted in the study; patients taking both aspirin&#xD;
             and clopidogrel are not permitted in the study;&#xD;
&#xD;
          -  Unable or unwilling to comply with the protocol;&#xD;
&#xD;
          -  Patient reported weight must be stable for the past 6 months (within 3kg variation);&#xD;
&#xD;
          -  Consumption of more than 14 standard alcoholic drinks a week.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Dufour, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Recherches Cliniques de Montreal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alberta Health Services Clinical Trials</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Abbotsford</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Diabetes</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dieppe</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Entralogix Clinical Research</name>
      <address>
        <city>Aurora</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Entralogix Clinical Research</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge Cardiac Care Center</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thamesview Ctr of Family Med</name>
      <address>
        <city>Chatam</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moran Medical Centre</name>
      <address>
        <city>Colingwood</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C &amp; L Research</name>
      <address>
        <city>Fort Erie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Entralogix Clinical Research</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Entralogix Clinical Research</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malton Medical Research Group</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Niagara Falls</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Entralogix Clinical Research</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taunton Health Centre</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steeple Hill Medical centre</name>
      <address>
        <city>Pickering</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.S. Cardiac Lab Medicine Professional Corp</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Entralogix Clinical Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eric Silver Medicine Professional Corporation</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Médicale des Trois Lacs</name>
      <address>
        <city>Vaudreuil Dorion</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Medicale Valcartier</name>
      <address>
        <city>Courcelette</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Reseau le Trait d'Union</name>
      <address>
        <city>Delson</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Medicale Mistassini</name>
      <address>
        <city>Dolbeau-Mistassini</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GMF Grand Mere</name>
      <address>
        <city>Grand Mere</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique medicale</name>
      <address>
        <city>Grand-Mere</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRM Lanaudiere</name>
      <address>
        <city>Joliette</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Applied Medical Information Research AMIR</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Services Sante Rosemere</name>
      <address>
        <city>Rosemere</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csss de St-Jerome</name>
      <address>
        <city>Saint-Jerome</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSSS Vallee De L'Or</name>
      <address>
        <city>Val d'Or</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Applied Medical Information Research (AMIR)</name>
      <address>
        <city>Westmount</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de recherche A&amp;E</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique des maladies lipidiques de Quebec Inc.</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>January 19, 2012</study_first_submitted>
  <study_first_submitted_qc>January 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <last_update_submitted>January 7, 2014</last_update_submitted>
  <last_update_submitted_qc>January 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertriglyceridemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

